Streetbeat News

HZNP

Horizon Therapeutics Plc

horizontherapeutics.com

CEO

Timothy P Walbert

Employees

1,440

Industry

Pharmaceutical Preparation Manufacturing

at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Open

116.34

Mkt cap

N/A

Volume

24M

High

116.34

P/E Ratio

61.86

52-wk high

116.34

Low

116.30

Div yield

N/A

52-wk low

116.30

Horizon Therapeutics's (NYSE:HZNP) short percent of float has fallen 25.18% since its last report, with 7.10 million shares sold short, which is 3.12% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. However, it does not necessarily mean that the stock price will rise in the near term. Compared to its peers, Horizon Therapeutics has less short interest.

Portfolio Pulse from Benzinga Insights

October 05, 2023 | 8:15 pm

Horizon Therapeutics' acquisition by Amgen has been approved by the High Court of Ireland. The acquisition was initially agreed upon on December 11, 2022, and is expected to be finalized on October 6, 2023, pending the delivery of the court order to the Registrar of Companies in Ireland.

Portfolio Pulse from Charles Gross

October 05, 2023 | 11:39 am

Horizon Therapeutics (NASDAQ:HZNP) has outperformed the market over the past 5 years by 36.06% on an annualized basis, producing an average annual return of 44.12%. If an investor had bought $100 of HZNP stock 5 years ago, it would be worth $640.52 today.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 4:30 pm

Horizon Therapeutics (NASDAQ:HZNP) has announced that new analyses of its drug UPLIZNA will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023. UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the FDA, the European Commission, and the Brazilian Health Regulatory Agency for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) in adults.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:14 pm

Horizon Therapeutics (NASDAQ:HZNP) has announced new data showing that disrupting the recommended TEPEZZA treatment regimen for Thyroid Eye Disease (TED) can increase the need for a second course of treatment. The majority of treatment disruptions were related to the short-term TEPEZZA supply disruption that occurred in late 2020 due to government-mandated COVID-19 vaccine production orders. The company also presented further results from the TEPEZZA Phase 4 clinical trial and research on the impact of TED on patients' quality of life.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 2:03 pm

Benzinga's options activity scanner has identified significant options activity in the Health Care sector. The stocks involved are BCLI, CVS, ICPT, ZBH, JNJ, EYPT, BBIO, REGN, ALGN, and HZNP. The options activity ranges from bullish to bearish sentiment, with varying expiration dates and strike prices.

Portfolio Pulse from Benzinga Insights

September 28, 2023 | 5:35 pm

Horizon Therapeutics's (NYSE:HZNP) short percent of float has risen 20.52% since its last report, indicating increased bearish sentiment. The company has 9.48 million shares sold short, which is 4.17% of all regular shares available for trading. This is higher than the peer group average of 3.45%. However, increased short interest can sometimes be bullish for a stock.

Portfolio Pulse from Benzinga Insights

September 18, 2023 | 2:15 pm

Q32 Bio and Horizon Therapeutics have dosed the first patient in a Phase 2 study of bempikibart in adult patients with severe alopecia areata. The companies are collaborating to develop bempikibart, an anti-IL-7Rα antibody that re-regulates adaptive immune function.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:08 pm

Q32 Bio and Horizon Therapeutics have announced the dosing of the first patient in a Phase 2 trial of Bempikibart for severe Alopecia Areata. Alopecia Areata is the second autoimmune indication being evaluated for Bempikibart.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:06 pm

Three health care stocks with over 3% dividend yields have been recommended by Wall Street's most accurate analysts. These include Amgen Inc. (NASDAQ:AMGN) with a dividend yield of 3.28%, Medtronic plc (NYSE:MDT) with a yield of 3.39%, and CVS Health Corporation (NYSE:CVS) with a yield of 3.52%. Recent news for these companies include FTC approval for Amgen's acquisition of Horizon Therapeutics Plc, FDA's recommendation against the approval of Medtronic's blood pressure treatment device, and FDA's warning to CVS Health for violating federal law.

Portfolio Pulse from Lisa Levin

September 13, 2023 | 11:35 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.